Definium Therapeutics Announces Topline Results From Its Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet In Major Depressive Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints

Loading news article.

Definium Therapeutics Announces Topline Results From Its Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet In Major Depressive Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints | WAPE

Definium Therapeutics Announces Topline Results From Its Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet In Major Depressive Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints

Article summary

Related companies

Comments —